ROTIGOTINE TRANSDERMAL PATCH IS EFFECTIVE IN THE TREATMENT OF IDIOPATHIC RLS: RESULTS OF A 6-MONTH, MULTICENTER, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL

W. Hening, R. Allen, P. Becker, R. Bogan, J. Fry, J. Keffel, D. Kudrow, K. Lesh, W. Ondo, E. Schollmayer, P. Vrooman, A. Walters, J. Winkelman on behalf of the SP792 study group

Objective:
To evaluate efficacy and safety of rotigotine transdermal patch in patients with moderate to severe idiopathic RLS.

Methods:
Multicenter, randomized, double-blind, placebo-controlled, 5-arm parallel-group trial with 4 fixed doses of rotigotine 0.5-3mg/24h (2.5-15cm²). IRLS sum score and the CGI item I are the co-primary efficacy parameters.

Results:
505 patients (52 ± 13 years, 61% female) were randomized at 58 sites in the US. The mean baselines scores were: IRLS 23.3±5.0 and CGI 4.7±0.7. For rotigotine at doses of 0.5, 1, 2, and 3mg/24h, improvement net effects versus placebo after 6 months treatment were -2.2±1.2, -2.3±1.2, -4.5±1.2(p<0.001), and -5.2±1.2(p<0.001) in the IRLS and -0.35±0.19, -0.32±0.19, -0.65±0.19(p<0.001) and -0.90±0.19(p<0.001) in CGI item I.
At least 1 adverse event was reported by 88% of patients. Most common side effects were application site reaction (27.2%), nausea(21.5%), headache(17.6%) and somnolence(12.6%). AEs were usually mild to moderate in intensity and transient.

Conclusion:
Therapy with rotigotine transdermal patch in doses of 2 and 3 mg/24h over a period of 6 months resulted in a statistically significant and clinically relevant reduction in the IRLS score and CGI item I compared to placebo and was well tolerated.